tiprankstipranks
Blurbs

RBC Capital Maintains a Hold Rating on PTC Therapeutics (PTCT)

In a report issued on July 7, Brian Abrahams from RBC Capital maintained a Hold rating on PTC Therapeutics (PTCTResearch Report), with a price target of $46.00. The company’s shares closed last Friday at $44.73, close to its 52-week high of $45.80.

According to TipRanks.com, Abrahams is a 1-star analyst with an average return of -1.0% and a 46.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PTC Therapeutics with a $47.43 average price target.

See Insiders’ Hot Stocks on TipRanks >>

PTC Therapeutics’ market cap is currently $3.14B and has a P/E ratio of -5.97.

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Read More on PTCT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More